TrialAnnals of the rheumatic diseases2022

Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study.

Eugen Feist et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.